| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
* From the Department of Anesthesiology, Buddhist Tzu-Chi Medical Center, Tzu-Chi University School of Medicine, Hualien; and the
Department of Anesthesiology and Department of Medical Research, Chi-Mei Medical Center, Tainan, Taiwan, ROC.
Address correspondence to: Dr. Yi Lee, Department of Anesthesiology, Buddhist Tzu-Chi Medical Center, Buddhist Tzu-Chi University School of Medicine, No. 707, Section 3, Chung-Yang Road, Hualien, Taiwan, ROC. E-mail: drleeyi2001{at}yahoo.com.tw
Purpose: Postoperative nausea and vomiting (PONV) occurs frequently after general anesthesia. We evaluated the timing of 2 mg iv doses of haloperidol on the efficacy of this drug as a prophylactic antiemetic for PONV.
Methods: Ninety-four non-smoking female patients with a history of motion sickness and/or PONV (Apfel’s simplified risk score = 3; predicted incidence of PONV = 60%) were eligible to participate in this randomized, double-blind study. Patients were divided into two groups. Group 1 patients received haloperidol 2 mg iv during induction of anesthesia. Group 2 patients received haloperidol 2 mg iv approximately 30 min before the end of surgery. The occurrence of nausea and vomiting, nausea scores, pain scores, sedation levels, and adverse effects (cardiac arrhythmias, and extrapyramidal effects) were recorded by a trained, blinded investigator.
Results: The percentages of patients who experienced PONV in the first 24 hr were similar for the two groups (Group 1 = 30%; Group 2 = 26%, P = 0.645). The incidence of PONV was significantly smaller in both groups than that predicted (60%) according to the patients’ underlying risks (Group 1, P = 0.004; Group 2, P = 0.001). Nausea scores, pain scores, sedation scores, emergence times, and time to first rescue treatment were similar in the two groups. No adverse effects attributable to the study medication were observed.
Conclusion: The timing of administration of haloperidol 2 mg iv does not influence its antiemetic efficacy. The recovery profiles were also similar whether haloperidol was administered at the start, or at the end of surgery.
1 Watcha MF, White PF. Postoperative nausea and vomiting. Its etiology, treatment, and prevention. Anesthesiology 1992; 77: 162–84.[Medline]
2 Henzi I, Sonderegger J, Tramer MR. Efficacy, doseresponse, and adverse effects of droperidol for prevention of postoperative nausea and vomiting. Can J Anesth 2000; 47: 537–51.
3 Habib AS, Gan TJ. Food and drug administration black box warning on the perioperative use of droperidol: a review of the cases. Anesth Analg 2003; 96: 1377–9.
4 Parlow JL, Costache I, Avery N, Turner K. Single-dose haloperidol for the prophylaxis of postoperative nausea and vomiting after intrathecal morphine. Anesth Analg 2004; 98: 1072–6.
5 Aouad MT, Siddik-Sayyid SM, Taha SK, et al. Haloperidol vs. ondansetron for the prevention of postoperative nausea and vomiting following gynaecological surgery. Eur J Anaesthesiol 2007; 24: 171–8.[Medline]
6 Gan TJ, Meyer T, Apfel CC, et al. Consensus guidelines for managing postoperative nausea and vomiting. Anesth Analg 2003; 97: 62–71.
7 Lee Y, Wang PK, Lai HY, Yang YL, Chu CC, Wang JJ. Haloperidol is as effective as ondansetron for preventing postoperative nausea and vomiting. Can J Anesth 2007; 54: 349–54.
8 Apfel CC, Laara E, Koivuranta M, Greim CA, Roewer N. A simplified risk score for predicting postoperative nausea and vomiting: conclusions from cross-validations between two centers. Anesthesiology 1999; 91: 693–700.[Medline]
9 Pierre S, Benais H, Pouymayou J. Apfel’s simplified score may favourably predict the risk of postoperative nausea and vomiting. Can J Anesth 2002; 49: 237–42.
10 Apfel CC, Roewer N, Korttila K. How to study postoperative nausea and vomiting. Acta Anaesthesiol Scand 2002; 46: 921–8.[Medline]
11 Chernik DA, Gillings D, Laine H, et al. Validity and reliability of the Observer’s Assessment of Alertness/ Sedation scale: study with intravenous midazolam. J Clin Psychopharmacol 1990; 10: 244–51.[Medline]
12 Tramer MR, Phillips C, Reynolds DJ, McQuay HJ, Moore RA. Cost-effectiveness of ondansetron for postoperative nausea and vomiting. Anaesthesia 1999; 54: 226–34.[Medline]
13 Lerman J. Study design in clinical research: sample size estimation and power analysis. Can J Anaesth 1996; 43: 184–91.
14 Gan TJ, Apfel CC, Kovac A, et al. A randomized, double blind comparison of the NK1 antagonist, aprepitant, versus ondansetron for the prevention of postoperative nausea and vomiting. Anesth Analg 2007; 104: 1082–9.
15 Barton MD, Libonati M, Cohen PJ. The use of haloperidol for treatment of postoperative nausea and vomiting: a double-blind placebo-controlled trial. Anesthesiology 1975; 42: 508–12.[Medline]
16 Buttner M, Walder B, von Elm E, Tramer MR. Is lowdose haloperidol a useful antiemetic? A meta-analysis of published and unpublished randomized trials. Anesthesiology 2004; 101: 1454–63.[Medline]
17 Vella-Brincat J, Macleod AD. Haloperidol in palliative care. Palliat Med 2004; 18: 195–201.
18 Forsman AO. Individual variability in response to haloperidol. Proc R Soc Med 1976; 69(suppl 1): 9–12.[Medline]
19 Fischler M, Bonnet F, Trang H, et al. The pharmacokinetics of droperidol in anesthetized patients. Anesthesiology 1986; 64: 486–9.[Medline]
20 Apfel CC, Kranke P, Eberhart LH, Roos A, Roewer N. Comparison of predictive models for postoperative nausea and vomiting. Br J Anaesth 2002; 88: 234–40.
21 Apfel CC, Kranke P, Katz MH, et al. Volatile anaesthetics may be the main cause of early but not delayed postoperative vomiting: a randomized controlled trial of factorial design. Br J Anaesth 2002; 88: 659–68.
22 Koivuranta M, Laara E, Snare L, Alahuhta S. A survey of postoperative nausea and vomiting. Anaesthesia 1997; 52: 443–9.[Medline]
23 Palazzo M, Evans R. Logistic regression analysis of fixed patient factors for postoperative sickness: a model for risk assessment. Br J Anaesth 1993; 70: 135–40.
24 Apfel CC, Greim CA, Haubitz I, et al. The discriminating power of risk score for postoperative vomiting in adults undergoing various types of surgery. Acta Anaesthesiol Scand 1998; 42: 502–9.[Medline]
25 Macleod AD. Use of sedatives in palliative medicine. Palliat Med 1997; 11: 493–4.
26 White PF, Song D, Abrao J, Klein KW, Navarette B. Effect of low-dose droperidol on the QT interval during and after general anesthesia: a placebo-controlled study. Anesthesiology 2005; 102: 1101–5.[Medline]
27 Sharma ND, Rosman HS, Padhi ID, Tisdale JE. Torsades de pointes associated with intravenous haloperidol in critically ill patients. Am J Cardiol 1998; 81: 238–40.[Medline]
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
